Alzheimer's disease (AD) is the most prevalent form of dementia. Despite decades of
research following several theoretical and clinical lines, all existing treatments for the …

There is accumulating evidence suggesting that changes in brain perfusion are present long
before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β …

Alzheimer's disease (AD) is associated with reduced temporo-parietal cerebral blood flow
(CBF). However, a substantial variability in CBF across the clinical spectrum of AD has been …

Background Dementia and mild cognitive impairment are characterised by symptoms of
cognitive decline, which are typically assessed using neuropsychological assessments …

Background: Emerging evidence suggests a role for orthostatic hypotension (OH) in
contributing to the progression of Alzheimer's disease (AD). The exosomes in the blood can …

Background: Subclinical cardiac dysfunction is associated with decreased cerebral blood
flow, placing the aging brain at risk for Alzheimer's disease (AD) pathology and …

We evaluated the diagnostic potential of 24S-hydroxycholesterol (24OHC) in cerebrospinal
fluid. At a memory clinic, we investigated subjects with subjective cognitive impairment (SCI …

Identification of biomarkers for the early stages of Alzheimer's disease (AD) is an imperative
step in developing effective treatments. Cerebral blood flow (CBF) is a potential early …

Background: Alzheimer's disease (AD), the most common form of dementia, remains long-
term and challenging to diagnose. Furthermore, there is currently no medication to …

Several studies have shown decreased cerebral blood flow (CBF) in Alzheimer's disease
(AD). However, the role of hypoperfusion in the disease pathogenesis remains unclear …